ArticleClinical ophthalmology (Auckland, N.Z.)2026
Long-Term Postoperative Outcomes of Micropulse Transscleral Cyclophotocoagulation (MP-TSCPC) in Patients with Glaucoma.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report long-term postoperative outcomes of micropulse transscleral cyclophotocoagulation (MP-TSCPC) in patients with glaucoma. Subjects and Methods: This study investigated 50 eyes in 45 patients (mean age: 67.5 ± 13.4 years) who underwent MP-TSCPC and had at least 24 months of postoperative follow-up. Causative diseases were primary open-angle glaucoma (38 eyes), pseudoexfoliation glaucoma (5 eyes), neovascular glaucoma (3 eyes), secondary glaucoma (3 eyes), and ocular hypertension (1 eye). Pre- and postoperative intraocular pressure (IOP), topical and/or oral medication scores, and complications were investigated retrospectively. Results: During the 24-month follow-up, 34 eyes (68%) underwent additional glaucoma intervention because of insufficient IOP control. Kaplan-Meier analysis showed probabilities of remaining free from additional intervention of 58.0% (95% confidence interval [CI], 43.2-70.2%) at 6 months, 48.0% (95% CI, 33.7-60.9%) at 12 months, and 32.0% (95% CI, 19.7-45.0%) at 24 months; the median additional-intervention-free time was 10 months. In the 16 eyes that remained free from additional intervention for 24 months, IOP decreased significantly at 1, 2, and 3 months compared with baseline after Holm correction (P < 0.05 each), but not at 6 months or later. Medication scores did not decrease. Previous glaucoma surgery was more frequent in eyes requiring additional intervention (41.2% vs 12.5%, P = 0.043). Mild or transient mydriasis occurred in 41 eyes (82%) and had resolved in 92% of affected eyes by 6 months. Conclusion: Most eyes required additional glaucoma intervention within 24 months after MP-TSCPC, and the probability of remaining free from additional intervention was 32.0% at 24 months. Among eyes not requiring additional intervention, the early IOP-lowering effect was not sustained beyond 3 months. MP-TSCPC remains a relatively nonincisional treatment option with few serious complications, but patients should be counseled regarding the frequent need for subsequent glaucoma intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.